YH IMD2Alternative Names: YH-IMD2; YH_IMD2
Latest Information Update: 10 Dec 2015
At a glance
- Originator Yuhan
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 10 Dec 2015 Discontinued - Preclinical for Hypertension in South Korea (PO)
- 10 Dec 2015 Discontinued - Preclinical for Hyperlipidaemia in South Korea (PO)
- 23 Aug 2012 Preclinical trials in Hyperlipidaemia in South Korea (PO)